
Researchers have identified a promising way to assess Alzheimer’s-related cognitive risks in otherwise healthy older adults.
A blood test could help estimate whether someone with no memory problems will develop cognitive impairment within the next five or 10 years. In a new Mayo Clinic study published in JAMA Neurology, researchers developed a method that combines an Alzheimer’s-related blood biomarker with age, sex, and genetic risk to produce personalized estimates.
For example, a 75-year-old woman without the APOE e4 genetic risk variant had an estimated five-year risk of mild cognitive impairment (MCI) of 5% when her biomarker level was relatively low. At a higher level, that estimate rose to 16%. Her predicted 10-year risk increased from 12% to 35%.
A Blood Test That Looks Beyond Alzheimer’s Biomarkers
The method measures phosphorylated Tau 217 (p-tau217), a protein associated with Alzheimer’s disease. Elevated levels in the blood are linked to Alzheimer’s-related changes in the brain, but a positive biomarker result alone cannot determine whether or when someone will develop cognitive symptoms.
“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” says Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher and first author of the study.
The research builds on an earlier Mayo Clinic prediction model that used positron emission tomography (PET) brain scans to detect amyloid, a protein that accumulates in the brains of people with Alzheimer’s disease. Measuring p-tau217 in blood offers a less invasive approach that could be used more widely.
How Age and Blood Biomarkers Shape Future Risk
Researchers analyzed data from 1,644 cognitively healthy participants in the Mayo Clinic Study of Aging and 534 participants in the Alzheimer’s Disease Neuroimaging Initiative. All were between 60 and 90 years old and had undergone blood biomarker measurements, genetic testing, and repeated cognitive assessments.
Using the Mayo Clinic data, the team calculated the probability of developing MCI or dementia within five or 10 years. Higher p-tau217 levels and older age were associated with greater risk. At the same elevated biomarker level, the estimated five-year risk of MCI was 6% for a 65-year-old but 37% for an 85-year-old.
The researchers then examined the Alzheimer’s Disease Neuroimaging Initiative data, which independently supported the association between elevated p-tau217 and increased risk of cognitive decline.
Could Earlier Risk Estimates Guide Alzheimer’s Prevention?
The approach could eventually help doctors identify people who might benefit from preventive treatment before memory problems begin. However, its clinical usefulness will depend partly on whether therapies can successfully delay cognitive decline in people who have no symptoms.
“A person may want to know: What is my risk of developing cognitive impairment in the next five or 10 years, and how does this blood test change that risk?” says Ronald Petersen, M.D., Ph.D., a Mayo Clinic neurologist and director of the Mayo Clinic Study of Aging. “If preventive therapies prove effective, those numbers could become very important in treatment decisions.”
Clinical trials, including AHEAD 3-45 and TRAILBLAZER-ALZ 3, are investigating whether treatments targeting amyloid can delay cognitive decline before symptoms develop. Both trials have used blood biomarkers to help identify participants, highlighting their potential role in earlier Alzheimer’s research.
Why More Research Is Still Needed
“Absolute risk gives the biomarker result clinical context,” says Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist and senior author of the study. “If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment.”
The risk estimates were developed using the Mayo Clinic Study of Aging and require further evaluation in more diverse populations and with other p-tau217 blood tests. Although the findings support the potential of personalized risk prediction, Alzheimer’s biomarker testing is not currently recommended for people without cognitive symptoms.
Reference: “Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4” by Alicia Algeciras-Schimnich, Mingzhao Hu, Stephen D. Weigand, et al., 16 November 2026, JAMA Neurology.
DOI: 10.1001/jamaneurol.2026.4292
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.